Boston Pharmaceutical Support
Boston Pharmaceutical Support is a Boston-based company dedicated to supporting the business and technical development of new chemical entities (NCEs) aimed at providing important new therapies for patients. They emphasize an ethical approach to clients' intellectual property and funds, extensive technical experience in chemical development for pharmaceutical APIs, and successful international collaborations. Their services include business development, scientific support, consultancy, and pharmaceutical quality/CMC support, with a focus on shortening development timelines while maintaining quality and integrity.
Industries
Nr. of Employees
small (1-50)
Boston Pharmaceutical Support
Boston, Massachusetts, United States, North America
Services
Representation and commercial engagement services for CROs and CDMOs, including partner introductions, pipeline presentations and licensing support.
End-to-end CRM development, hosting, implementation and post-deployment training tailored to pharma R&D service providers.
Technical and commercial evaluation of outsourcing options, provider reports, partner selection and integration planning.
Process research, route optimisation and scale-up advisory for API manufacture and intermediates, including use of continuous and specialist reaction technologies.
Regulatory and quality support for INDs, NDAs, ANDAs and DMFs, analytical method validation and related CMC documentation.
Sales team training and private coaching focused on business development, proposal presentation and sales process engineering.
Representation and commercial engagement services for CROs and CDMOs, including partner introductions, pipeline presentations and licensing support.
End-to-end CRM development, hosting, implementation and post-deployment training tailored to pharma R&D service providers.
Technical and commercial evaluation of outsourcing options, provider reports, partner selection and integration planning.
Process research, route optimisation and scale-up advisory for API manufacture and intermediates, including use of continuous and specialist reaction technologies.
Regulatory and quality support for INDs, NDAs, ANDAs and DMFs, analytical method validation and related CMC documentation.
Sales team training and private coaching focused on business development, proposal presentation and sales process engineering.
Expertise Areas
- Business development for CROs and CDMOs
- CRM implementation for life-sciences service providers
- Process development and scale-up for APIs
- Synthetic chemistry and route optimisation
Key Technologies
- CRM platforms and sales-force automation
- Continuous flow and loop reactor processing
- Vapor-phase chemical reactions
- cGMP manufacturing for clinical materials
News & Updates
Shire is a biotech company that is focused on serving people with rare diseases and other specialized conditions. Shares of Shire PLC (SHPG) were gaining by more than 3% to $168.97 on Wednesday, following talk of a takeover of the specialty drug maker.
Shares of Alexion Pharmaceuticals Inc. (ALXN) rose 6.7% to $139.88 in premarket trading on Thursday, July 27, after the New Haven, Conn.-based firm unveiled second-quarter results.
Tetraphase Pharmaceuticals reported positive results in a Phase 3 study of its antibiotic eravacycline, which could support approval in Europe and the US. The drug is being developed to handle multiple bacterial infections, addressing the rise of drug-resistant bugs.
Shire is a biotech company that is focused on serving people with rare diseases and other specialized conditions. Shares of Shire PLC (SHPG) were gaining by more than 3% to $168.97 on Wednesday, following talk of a takeover of the specialty drug maker.
Shares of Alexion Pharmaceuticals Inc. (ALXN) rose 6.7% to $139.88 in premarket trading on Thursday, July 27, after the New Haven, Conn.-based firm unveiled second-quarter results.
Tetraphase Pharmaceuticals reported positive results in a Phase 3 study of its antibiotic eravacycline, which could support approval in Europe and the US. The drug is being developed to handle multiple bacterial infections, addressing the rise of drug-resistant bugs.